TY - JOUR
T1 - Outcomes after atrioventricular node ablation and biventricular pacing in patients with refractory atrial fibrillation and heart failure
T2 - A comparison between non-ischaemic and ischaemic cardiomyopathy
AU - Sohinki, Daniel
AU - Ho, Jeffrey
AU - Srinivasan, Nishant
AU - Collins, Laura J.
AU - Obel, Owen A.
PY - 2014/6
Y1 - 2014/6
N2 - Aims: Atrioventricular junction ablation (AVJA) combined with biventricular (BiV) pacing (AVJA/BiV) is an effective treatment for refractory atrial fibrillation (AF) and rapid ventricular response (RVR) associated with heart failure (HF). This study compared the outcomes between patients with non-ischaemic (DCM) and ischaemic cardiomyopathy (ICM) following AVJA/BiV for AF/RVR. Methods and results: This was a retrospective study of 45 patients, comparing the response to AVJA/BiV in patients with ICM to those with DCM. The study compared (a) the change in echocardiographic parameters of HF (ejection fraction (EF) and left ventricular dimensions) prior to, and at least 6 months post AVJA/BiV; and (b) HF hospitalizations (HFH) and appropriate implantable cardioverter defibrillator (ICD) therapies occurring post-procedure. Ejection fraction improved significantly in the DCM group (ΔEF 11.2 ± 11.9; P< 0.01); however, EF remained unchanged (ΔEF 0.5 ± 9.9; P NS) in the ICM group post-AVJA/BiV. Post-procedurely, HFH were significantly more common (15/18 vs. 4/25; P < 0.0001), and there were significantly more appropriate ICD therapies (9.4 ± 12.3 vs. 2.3 ± 6.1; P 0.01) in the ICM compared with the DCM group. Conclusion: After AVJA/BiV, there was significantly less post-procedural echocardiographic reverse remodelling, and more HFH in the ICM compared with the DCM group. In addition, significantly more appropriate ICD therapies occurred in ICM patients post-procedure. These differences may be due to the presence of more extensive discrete myocardial scar in patients with ICM. Furthermore, it is possible that tachycardia-induced cardiomyopathy plays more of a causative role in HF in patients with AF and DCM than those with ICM.
AB - Aims: Atrioventricular junction ablation (AVJA) combined with biventricular (BiV) pacing (AVJA/BiV) is an effective treatment for refractory atrial fibrillation (AF) and rapid ventricular response (RVR) associated with heart failure (HF). This study compared the outcomes between patients with non-ischaemic (DCM) and ischaemic cardiomyopathy (ICM) following AVJA/BiV for AF/RVR. Methods and results: This was a retrospective study of 45 patients, comparing the response to AVJA/BiV in patients with ICM to those with DCM. The study compared (a) the change in echocardiographic parameters of HF (ejection fraction (EF) and left ventricular dimensions) prior to, and at least 6 months post AVJA/BiV; and (b) HF hospitalizations (HFH) and appropriate implantable cardioverter defibrillator (ICD) therapies occurring post-procedure. Ejection fraction improved significantly in the DCM group (ΔEF 11.2 ± 11.9; P< 0.01); however, EF remained unchanged (ΔEF 0.5 ± 9.9; P NS) in the ICM group post-AVJA/BiV. Post-procedurely, HFH were significantly more common (15/18 vs. 4/25; P < 0.0001), and there were significantly more appropriate ICD therapies (9.4 ± 12.3 vs. 2.3 ± 6.1; P 0.01) in the ICM compared with the DCM group. Conclusion: After AVJA/BiV, there was significantly less post-procedural echocardiographic reverse remodelling, and more HFH in the ICM compared with the DCM group. In addition, significantly more appropriate ICD therapies occurred in ICM patients post-procedure. These differences may be due to the presence of more extensive discrete myocardial scar in patients with ICM. Furthermore, it is possible that tachycardia-induced cardiomyopathy plays more of a causative role in HF in patients with AF and DCM than those with ICM.
KW - AV node ablation
KW - Atrial fibrillation
KW - Biventricular pacing
KW - Ischaemic cardiomyopathy
KW - Non-ischaemic cardiomyopathy
UR - http://www.scopus.com/inward/record.url?scp=84901828793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901828793&partnerID=8YFLogxK
U2 - 10.1093/europace/eut392
DO - 10.1093/europace/eut392
M3 - Article
C2 - 24525552
AN - SCOPUS:84901828793
SN - 1099-5129
VL - 16
SP - 880
EP - 886
JO - Europace
JF - Europace
IS - 6
ER -